These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12003405)

  • 1. Acute pancreatitis associated with rofecoxib.
    Amaravadi RK; Jacobson BC; Solomon DH; Fischer MA
    Am J Gastroenterol; 2002 Apr; 97(4):1077-8. PubMed ID: 12003405
    [No Abstract]   [Full Text] [Related]  

  • 2. Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: coprecipitants or coincidence?
    Goh J; Wight D; Parkes M; Middleton SJ; Hunter JO
    Am J Gastroenterol; 2002 Apr; 97(4):1061-2. PubMed ID: 12003391
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe cholestasis and acute renal failure related to rofecoxib.
    Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J
    Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib.
    Gornet JM; Hassani Z; Modiglian R; Lémann M
    Am J Gastroenterol; 2002 Dec; 97(12):3209-10. PubMed ID: 12492220
    [No Abstract]   [Full Text] [Related]  

  • 6. Ischemic colitis associated with rofecoxib.
    Radaelli F; Feltri M; Meucci G; Spinzi G; Terruzzi V; Minoli G
    Dig Liver Dis; 2005 May; 37(5):372-6. PubMed ID: 15843089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocytoclastic vasculitis related to rofecoxib.
    Palop-Larrea V; Melchor-Penella MA; Ortega-Monzó C; Martínez-Mir I
    Ann Pharmacother; 2003 Nov; 37(11):1731-2. PubMed ID: 14565803
    [No Abstract]   [Full Text] [Related]  

  • 8. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 9. Rofecoxib does not adversely affect skin graft survival in a rat model.
    Miller Q; Losken A; Harre JG; Bird ME
    Curr Surg; 2004; 61(2):227-30. PubMed ID: 15051270
    [No Abstract]   [Full Text] [Related]  

  • 10. Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
    Can Fam Physician; 2005 Feb; 51(2):212-3. PubMed ID: 15751564
    [No Abstract]   [Full Text] [Related]  

  • 11. Lessons learned after the withdrawal of rofecoxib.
    Giaquinta D
    Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons on prescribing and drug safety from the withdrawal of rofecoxib.
    Nelson M; Cicuttini F
    Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rofecoxib-induced aquagenic edema with puckering of the palms of the hands: the first case].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):813. PubMed ID: 14576620
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute cholestatic hepatitis associated with long-term use of rofecoxib.
    Papachristou GI; Demetris AJ; Rabinovitz M
    Dig Dis Sci; 2004 Mar; 49(3):459-61. PubMed ID: 15139498
    [No Abstract]   [Full Text] [Related]  

  • 19. [Role of allopurinol and rofecoxib in agranulocytosis and acute tubular necrosis].
    Real Panisello M; Vila Clérigues N; García Reina L; Luaces Vidal F; González Ponce CM; Díaz Carrasco MS
    Farm Hosp; 2003; 27(5):317-22. PubMed ID: 14576922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.